Asset Details
Do you wish to reserve the book?
Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)
Do you wish to request the book?
Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)
2019
Overview
BackgroundSmall cell lung cancer (SCLC) accounts for 10–15% of all lung malignancies and its prognosis is dismal. Although early studies have shown promising clinical activity of immune checkpoint blockers, the immune composition and expression of potentially actionable immunostimulatory targets in this malignancy are poorly understood.MethodsUsing multiplexed quantitative immunofluorescence (QIF), we measured the levels of 3 different B7 family ligands PD-L1, B7-H3, B7-H4 and major tumor infiltrating lymphocyte (TIL) subsets in 90 SCLC samples represented in tissue microarray format. Associations between the marker levels, clinicopathological variables and survival were studied.ResultsPD-L1 protein was detected in 7.3%, B7-H3 in 64.9% and B7-H4 in 2.6% of SCLC cases. The markers showed limited co-expression and were not associated with the level of TILs, age, gender and stage. Elevated B7-H4 was associated with shorter 5-year overall survival. The levels of CD3+, CD8+ and CD20+ TILs and the ratio of total/effector T-cells were significantly lower in SCLC than in non-small cell lung cancer. High levels of CD3+, but not CD8+ or CD20+ TILs were significantly associated with longer survival.ConclusionsTaken together, our study indicate variable expression and clinical role of B7-family ligands in SCLC with predominant expression of the candidate target B7-H3 and the presence of a limited cytotoxic anti-tumor immune response. These results support the evaluation of B7-H3 blockers and/or pro-inflammatory therapies in SCLC.
Publisher
BMJ Publishing Group Ltd,BioMed Central,BioMed Central Ltd,BMJ Publishing Group LTD,BMJ Publishing Group
Subject
/ Antigens
/ Cancer
/ EDTA
/ Female
/ Fluorescent Antibody Technique
/ Humans
/ Lymphocytes, Tumor-Infiltrating - immunology
/ Lymphocytes, Tumor-Infiltrating - metabolism
/ Lymphocytes, Tumor-Infiltrating - pathology
/ Male
/ Medicine
/ Oncology
/ Proteins
/ Small Cell Lung Carcinoma - etiology
/ Small Cell Lung Carcinoma - metabolism
/ Small Cell Lung Carcinoma - mortality
/ Small Cell Lung Carcinoma - pathology
/ T cells
/ Tumors
/ V-Set Domain-Containing T-Cell Activation Inhibitor 1 - genetics
/ V-Set Domain-Containing T-Cell Activation Inhibitor 1 - metabolism
